Are you preparing to advance your cancer technology from Phase II to commercialization? The Phase IIB Bridge Award is designed to help you cross the funding “Valley of Death” that occurs between Phase II and commercialization.
This opportunity provides up to $4 million in additional funding over 3 years to Phase II SBIR/STTR projects. The aim of the Bridge Award is for awardees to attract follow-on funding from third-party investors and/or strategic partners. You can find the Funding Opportunity Announcement (FOA) RFA-CA-22-025 at the hyperlink.
Letter of Intent Due Date: July 5, 2022, by 5:00 PM local time. SBIR & STTR projects from other Federal agencies are welcome to apply. Check Section III of the FOA for detailed eligibility criteria.
Projects must address one of the following areas:
- Cancer Therapeutics
- Imaging Technologies
- Interventional Devices
- Diagnostics
- Prognostics
For more information regarding the SBIR Phase IIB Bridge Award and eligibility requirements, join our FREE WEBINAR on June 9 at 2:00 pm ET.
Before applying, interested small businesses should send in a letter of intent by Tuesday, July 5, 2022. The application deadline for the Phase IIB Bridge award is Friday, August 5, 2022.
Please visit the Bridge Award page or the funding opportunity announcement
(RFA-CA-22-025) for more information about the opportunity. If you would like to discuss your eligibility and more, please contact NCI SBIR Program Director Jonathan Franca-Koh at francakohj@mail.nih.gov.
